000285301 001__ 285301
000285301 005__ 20240229155107.0
000285301 0247_ $$2doi$$a10.1093/neuonc/noad195
000285301 0247_ $$2pmid$$apmid:37944912
000285301 0247_ $$2ISSN$$a1522-8517
000285301 0247_ $$2ISSN$$a1523-5866
000285301 0247_ $$2altmetric$$aaltmetric:156263259
000285301 037__ $$aDKFZ-2023-02322
000285301 041__ $$aEnglish
000285301 082__ $$a610
000285301 1001_ $$00000-0003-3099-5259$$aFangusaro, Jason$$b0
000285301 245__ $$aPediatric low-grade glioma: State-of-the-art and ongoing challenges.
000285301 260__ $$aOxford$$bOxford Univ. Press$$c2024
000285301 3367_ $$2DRIVER$$aarticle
000285301 3367_ $$2DataCite$$aOutput Types/Journal article
000285301 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1705658337_22126
000285301 3367_ $$2BibTeX$$aARTICLE
000285301 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000285301 3367_ $$00$$2EndNote$$aJournal Article
000285301 500__ $$a2024 Jan 5;26(1):25-37
000285301 520__ $$aThe most common childhood central nervous system (CNS) tumor is pediatric low-grade glioma (pLGG), representing 30%-40% of all CNS tumors in children. Although there is high associated morbidity, tumor-related mortality is relatively rare. pLGG is now conceptualized as a chronic disease, underscoring the importance of functional outcomes and quality-of-life measures. A wealth of data has emerged about these tumors, including a better understanding of their natural history and their molecular drivers, paving the way for the use of targeted inhibitors. While these treatments have heralded tremendous promise, challenges remain about how to best optimize their use, and the long-term toxicities associated with these inhibitors remain unknown. The International Pediatric Low-Grade Glioma Coalition (iPLGGc) is a global group of physicians and scientists with expertise in pLGG focused on addressing key pLGG issues. Here, the iPLGGc provides an overview of the current state-of-the-art in pLGG, including epidemiology, histology, molecular landscape, treatment paradigms, survival outcomes, functional outcomes, imaging response, and ongoing challenges. This paper also serves as an introduction to 3 other pLGG manuscripts on (1) pLGG preclinical models, (2) consensus framework for conducting early-phase clinical trials in pLGG, and (3) pLGG resistance, rebound, and recurrence.
000285301 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000285301 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000285301 650_7 $$2Other$$aMAPK/ERK pathway
000285301 650_7 $$2Other$$aoverview
000285301 650_7 $$2Other$$apediatric low-grade glioma
000285301 650_7 $$2Other$$atargeted therapy
000285301 7001_ $$0P:(DE-He78)551bb92841f634070997aa168d818492$$aJones, David T$$b1$$udkfz
000285301 7001_ $$aPacker, Roger J$$b2
000285301 7001_ $$aGutmann, David H$$b3
000285301 7001_ $$0P:(DE-He78)0be2f86573954f87e97f8a4dbb05cb0f$$aMilde, Till$$b4$$udkfz
000285301 7001_ $$0P:(DE-He78)143af26de9d57bf624771616318aaf7c$$aWitt, Olaf$$b5$$udkfz
000285301 7001_ $$aMueller, Sabine$$b6
000285301 7001_ $$aJ Fisher, Michael$$b7
000285301 7001_ $$aHansford, Jordan R$$b8
000285301 7001_ $$00000-0002-5019-2683$$aTabori, Uri$$b9
000285301 7001_ $$aHargrave, Darren$$b10
000285301 7001_ $$00000-0002-4175-4760$$aBandopadhayay, Pratiti$$b11
000285301 773__ $$0PERI:(DE-600)2094060-9$$a10.1093/neuonc/noad195$$gp. noad195$$n1$$p25-37$$tNeuro-Oncology$$v26$$x1522-8517$$y2024
000285301 909CO $$ooai:inrepo02.dkfz.de:285301$$pVDB
000285301 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)551bb92841f634070997aa168d818492$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000285301 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0be2f86573954f87e97f8a4dbb05cb0f$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000285301 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)143af26de9d57bf624771616318aaf7c$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000285301 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000285301 9141_ $$y2023
000285301 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-24$$wger
000285301 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOLOGY : 2022$$d2023-10-24
000285301 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-24
000285301 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-24
000285301 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-24
000285301 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-24
000285301 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-24
000285301 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-24
000285301 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-24
000285301 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-24
000285301 915__ $$0StatID:(DE-HGF)9915$$2StatID$$aIF >= 15$$bNEURO-ONCOLOGY : 2022$$d2023-10-24
000285301 9201_ $$0I:(DE-He78)B360-20160331$$kB360$$lPädiatische Gliomforschung$$x0
000285301 9201_ $$0I:(DE-He78)B310-20160331$$kB310$$lKKE Pädiatrische Onkologie$$x1
000285301 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000285301 980__ $$ajournal
000285301 980__ $$aVDB
000285301 980__ $$aI:(DE-He78)B360-20160331
000285301 980__ $$aI:(DE-He78)B310-20160331
000285301 980__ $$aI:(DE-He78)HD01-20160331
000285301 980__ $$aUNRESTRICTED